Full Breakdown
Hims Expands Direct-to-Consumer Testosterone Therapy
By Drooid · · How we work
Background: Rising Interest in Low-T Care
Low testosterone affects an estimated 20 million men in the United States, a figure cited by Hims & Hers Health, Inc. (NYSE: HIMS). Untreated deficiency is linked to reduced energy, loss of lean muscle, diminished sex drive, erectile dysfunction, and higher risk of metabolic syndrome, diabetes, obesity, and cardiovascular disease. A Hims-commissioned survey of 2,000 U.S. men aged 18 and older found that 79 percent prioritize more energy over greater muscle mass, while only 45 percent say they are familiar with specific low-T treatments. The same poll highlighted growing openness among men to discuss hormone health.
Service Details and Delivery Model
Hims now offers two injectable formulations and an oral pill (Kyzatrex®) for eligible patients. The injectable options include a twice-weekly subcutaneous compound and a once-weekly intramuscular testosterone cypionate; the oral formulation is FDA-approved and reportedly helps up to 96 percent of users achieve normal testosterone levels within 90 days. All patients begin with an at-home capillary blood draw using the FDA-cleared Tasso® device, which collects a small sample from the upper arm without a venous draw. The sample is analyzed for 22 biomarkers—including total and free testosterone, SHBG, lipid panels, and glycemic markers—by Hims’ partner lab. Licensed providers review the results, medical history, and symptoms in a live telehealth visit before prescribing treatment deemed “medically appropriate.” Ongoing monitoring, follow-up labs, and support teams are built into the care pathway.
Data & Statistics
- Affected population: ? 20 million U.S. men.
- Survey size: 2,000 men.
- Priority outcome: 79 % seek more energy over muscle gain.
- Treatment awareness: 45 % familiar with low-T therapies.
- Oral TRT efficacy: up to 96 % reach normal levels in 90 days.
- Growth rate: Hims reports testosterone services scaling faster than any other specialty outside weight-loss within three quarters of launch (company press release).
Official Statements & Responses
Hims’ leadership framed the launch as the “largest and most important expansion” of its men’s health program, emphasizing that the new options “build on” its existing Testosterone Rx+ regimen, which includes enclomiphene to boost endogenous hormone production. The company stresses that its at-home testing removes traditional barriers—such as scheduling lab visits and confronting stigma—while preserving clinical rigor. Hims also notes that, as of the second quarter, testosterone services are expanding more rapidly than any other specialty outside weight-loss.
Verbatim Quotes
- “When we first started, we didn't have the capabilities to take care of a complex condition like testosterone deficiency,” — Peter Stahl, senior vice president of men’s health at Hims
- “Treating testosterone deficiency isn’t just about improving a lab result,” — Related Stories Hims
Potential Concerns
No formal regulatory challenges have been reported in connection with the new TRT offerings.
What’s Next
Hims indicates that the expanded testosterone portfolio will continue to be integrated with its broader men’s health services, with ongoing data collection to refine treatment protocols and support. No specific future milestones or regulatory reviews were disclosed.